Abstract

Ischemic brain injury provokes complex, time-dependent downstream pathways that ultimately lead to cell death. We aimed to demonstrate the levels of a wide range of metabolites in brain lysates and their on-tissue distribution following neonatal stroke and cell therapies. Postnatal day 12 mice underwent middle cerebral artery occlusion (MCAO) and were administered 1 × 105 cells after 48 h. Metabolomic analysis of the injured hemisphere demonstrated that a variety of amino acids were significantly increased and that tricarboxylic acid cycle intermediates and some related amino acids, such as glutamate, were decreased. With the exception of the changes in citric acid, neither mesenchymal stem/stromal cells nor CD34+ cells ameliorated these changes. On-tissue visualization with matrix-assisted laser desorption/ionization-mass spectrometry (MALDI-MS) imaging revealed that the signal intensity of glutamate was significantly decreased in the infarct area, consistent with the metabolomic analysis, while its intensity was significantly increased in the peri-infarct area after MCAO. Although cell therapies did not ameliorate the changes in metabolites in the infarct area, mesenchymal stem cells ameliorated the increased levels of glutamate and carnitine in the peri-infarct area. MALDI-MS imaging showed the location-specific effect of cell therapies even in this subacute setting after MCAO. These methodologies may be useful for further investigation of possible treatments for ischemic brain injury.

Highlights

  • Ischemic brain injury provokes complex, time-dependent downstream pathways that lead to cell death

  • Our previous reports showed that both human umbilical cord blood ­CD34+ cell- and human umbilical-cord-derived mesenchymal stem/stromal cell (MSC)-based therapies applied 48 h after permanent middle cerebral artery occlusion (MCAO) had neuroprotective effects, which occurred through the modulation of the inflammatory reaction and the recovery of cerebral blood flow rather than by cell replacement at the injured site or cellular secretion of brain-derived neurotrophic factor (BDNF)[3,4]

  • Neonatal mice were divided into four groups: no-surgery control, MCAO-vehicle, MCAO-CD34+ cell, and MCAO-MSC (n = 5 in each group)

Read more

Summary

Introduction

Ischemic brain injury provokes complex, time-dependent downstream pathways that lead to cell death. MALDI-MS imaging showed the location-specific effect of cell therapies even in this subacute setting after MCAO These methodologies may be useful for further investigation of possible treatments for ischemic brain injury. We demonstrated the changes in metabolites following MCAO and the two cell therapies through metabolomic analysis of homogenized tissue samples and MS imaging of tissue sections, which shows location-specific information.

Objectives
Methods
Results
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call